Fast Market Research announces the availability of the new Global Markets Direct report, "Meningioma - Pipeline Review, H1 2017", on their comprehensive research portal
Boston, MA -- (SBWIRE) -- 07/11/2017 -- Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Meningioma - Pipeline Review, H1 2017, provides an overview of the Meningioma (Oncology) pipeline landscape.
A meningioma is a type of tumor that develops from the meninges, the membrane that surrounds the brain and spinal cord. There are three layers of meninges, called the dura mater, arachnoid and pia mater. Most meningiomas (90%) are categorized as benign tumors, with the remaining 10% being atypical or malignant. There is no obvious cause of a meningioma. However, this type of brain tumor is about three times more common in women than in men. A meningioma can cause symptoms by pressing on the brain or spinal cord.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Meningioma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Meningioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Get More Details on this Report and a Full Table of Contents at Meningioma - Pipeline Review, H1 2017
The Meningioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Meningioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Phase 0 stages are 5, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Meningioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
-The pipeline guide provides a snapshot of the global therapeutic landscape of Meningioma (Oncology).
-The pipeline guide reviews pipeline therapeutics for Meningioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
-The pipeline guide reviews key companies involved in Meningioma (Oncology) therapeutics and enlists all their major and minor projects.
-The pipeline guide evaluates Meningioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
-The pipeline guide reviews latest news related to pipeline therapeutics for Meningioma (Oncology)
Reasons to Get this Report
-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
-Find and recognize significant and varied types of therapeutics under development for Meningioma (Oncology).
-Classify potential new clients or partners in the target demographic.
-Develop tactical initiatives by understanding the focus areas of leading companies.
-Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
-Formulate corrective measures for pipeline projects by understanding Meningioma (Oncology) pipeline depth and focus of Indication therapeutics.
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Companies Mentioned in this Report: Arno Therapeutics Inc, AstraZeneca Plc, Boehringer Ingelheim GmbH, GlaxoSmithKline Plc, Novartis AG, Pharma Mar SA, Progenics Pharmaceuticals Inc
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Drug Pipeline research reports at Fast Market Research
You may also be interested in these related reports:
-Herpes Zoster (Shingles) - Pipeline Review, H1 2017
-Bronchitis - Pipeline Review, H1 2017
-Gastric Cancer - Pipeline Review, H1 2017
-Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2017
-Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2017